VivoSeq
Infectious Disease

Herpes Labialis

13

Pipeline Programs↗

0

Active Trials↗

9

Companies Involved↗

Herpes Labialis is an emerging landscape with 13 programs across 9 companies. The most active players are Sanofi, Otsuka, Bayer. 4 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

60/100

Completion Rate

81/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 3M

Meda Pharmaceuticals

1 program

Phase 3N

Nobias Therapeutics, Inc.

1 program

Phase 3Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

19

clinical trials

Completed13 · 68%
Unknown status3 · 16%
Terminated3 · 16%

Clinical Trials

Trial Activity

19 trials

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Completed·Bayer logoBayer·Phase 3·NCT05098938·2,020 enrolled
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
Completed·NNanoBio Corporation·Phase 2·NCT00453401·1,000 enrolled
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
Completed·Novartis logoNovartis·Phase 4·NCT00248144
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)
Completed·NNanoBio Corporation·Phase 3·NCT01324466·847 enrolled
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
Completed·Novartis logoNovartis·Phase 2/3·NCT00878072·53 enrolled
Place Controlled Study to Treat Recurrent Herpes Labialis.
Completed·UUniversity of Zurich·Phase 2·NCT00914745·40 enrolled
Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes Labialis
Completed·MMedivir·Phase 2·NCT00736437·417 enrolled
Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
Completed·MMassachusetts General Hospital·Phase 1·NCT01971385·54 enrolled
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis
Completed·NNanoBio Corporation·Phase 3·NCT01321359·907 enrolled
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
Completed·MMeda Pharmaceuticals·Phase 3·NCT01574612·54 enrolled
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Completed·EEMS·Phase 3·NCT01257074·76 enrolled
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
Completed·UUniversity of Utah·Phase 2·NCT00297011·300 enrolled
Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
Completed·SSquarex, LLC·Phase 1/2·NCT02965781·139 enrolled
Botulinum Toxin A for Herpes Labialis
Terminated·DDeNova Research·N/A·NCT01225341·20 enrolled
A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00913692·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)